ClinicalTrials.gg
CompletedNCT03267303Updated Feb 28, 2025

A Study to Evaluate the Safety and Efficacy of TS-091 in Patients with Narcolepsy

A Phase 2 interventional study of TS-091 5mg and TS-091 10mg in Narcolepsy, sponsored by Taisho Pharmaceutical Co., Ltd.. Completed at 2 sites in 2 countries. Open to participants aged 16 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by Taisho Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
16 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 13 studies in Narcolepsy with a site in Japan — 5 open to participants now, 5 under way, 2 of them phase 3. Narcolepsy · Japan.

Enrollment
12th of 13
53 · median 88
Started
2017
with 1 other
Phase 2
8 of 13
3 open now
Registered
1st of 13
by date
Lead sponsor
1 of 13
Taisho Pharmaceutical Co., Ltd.

Among the 13 studies in Narcolepsy with a site in Japan, this one is the 12th largest by enrollment, is one of 2 that started in 2017, is one of 8 in phase 2, and was the 1st registered.

Narcolepsy

158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.

Browse Narcolepsy studies →

Open to participants now

5 of the 13 studies in Narcolepsy with a site in Japan are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 16 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Narcolepsy with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the efficacy and safety after administration of TS-091 compared with placebo in patients with narcolepsy.

03

Conditions studied

  • Narcolepsy

Browse trials for

Keywords

  • Narcolepsy
04

Who can participate

Ages eligible
16 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients diagnosed with narcolepsy type 1 or type 2 based on the International Classification of Sleep Disorders, third edition (ICSD-3) criteria
  2. Patients aged ≥16 to \<65 years at the time of obtaining
  3. Outpatients

Exclusion criteria

Exclusion Criteria:

  1. Patients with sleep disorders other than narcolepsy (e.g., sleep apnea syndrome, periodic limb movement disorder)
  2. Patients with organic brain diseases (including neurodegenerative diseases or cerebrovascular disorders) or epilepsy
  3. Patients with obstructive respiratory diseases (bronchial asthma, emphysema)
  4. Patients with psychiatric disorders (e.g., major depressive disorder, bipolar disorder, schizophrenia)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    TS-091 5mg

    Drug: TS-091 5mg

  • Experimental
    TS-091 10mg

    Drug: TS-091 10mg

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugTS-091 5mg

    Orally taken once daily for 3 weeks

  • DrugTS-091 10mg

    Orally taken once daily for 3 weeks

  • DrugPlacebo

    Orally taken once daily for 3 weeks

06

What researchers measure

Primary outcomes

  1. Mean sleep latency in maintenance of wakefulness test

    Time frame: 3 weeks

Secondary outcomes

  1. Total score on the epworth sleepiness scale

    Time frame: 3 weeks

07

Study locations

2 sites
  • Taisho Pharmaceutical Co., Ltd selected site
    Osaka and other Japanese city, Japan
  • Taisho Pharmaceutical Co., Ltd selected site
    Seoul and other Korean city, Korea, Republic of
08

References and documents

Publications

  • Inoue Y, Uchiyama M, Umeuchi H, Onishi K, Ogo H, Kitajima I, Matsushita I, Nishino I, Uchimura N. Optimal dose determination of enerisant (TS-091) for patients with narcolepsy: two randomized, double-blind, placebo-controlled trials. BMC Psychiatry. 2022 Feb 22;22(1):141. doi: 10.1186/s12888-022-03785-7. PubMed 35193545 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Dec 2018, 13 months.

Of 15 phase 2 interventional studies under Narcolepsy, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's 13 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2017
First posted
Aug 30, 2017
StartActual
Oct 31, 2017
Primary completionActual
Dec 13, 2018
CompletionActual
Aug 8, 2019
Last update
Feb 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03267303
Responsible party
Sponsor
First posted
Aug 30, 2017
Start date
Oct 31, 2017
Primary completion
Dec 13, 2018
Completion
Aug 8, 2019
Last update
Feb 28, 2025

Study contacts

Shigeru Okuyama
study director · Taisho Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion